<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">已經(jīng)成為藥劑學(xué)研發(fā)中非常常用的一種藥用高分子材料，其優(yōu)越性已被越來越多地認識，使它成為一種成熟

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的多用途藥用輔料。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">是由<***N style="FONT-SIZE: 9pt" lang=EN-US>N-<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">**基<***N style="FONT-SIZE: 9pt" lang=EN-US>-2-<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">吡喏烷酮單體催化生成的水溶性聚合物，極易吸濕結(jié)塊，易溶于水和乙

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">醇等極性有機溶劑是其應(yīng)用特點之一。藥用聚維酮分子量在<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">萬<***N style="FONT-SIZE: 9pt" lang=EN-US>-70<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">萬之間，一般以<***N style="FONT-SIZE: 9pt" lang=EN-US>K<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">之大小表示，<***N style="FONT-SIZE: 9pt" lang=EN-US>K<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">越大，分子

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">量越高如下表。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有許多優(yōu)良的性質(zhì)，其在藥劑學(xué)中應(yīng)用也越來越廣泛，適用面越來越多，下面就對其在國內(nèi)

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在藥物制劑開發(fā)研究中應(yīng)用的主要方面做一下總結(jié)。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">規(guī)<***N style="FONT-SIZE: 9pt"> <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">格<***N style="FONT-SIZE: 9pt" lang=EN-US> (<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">分子量<***N style="FONT-SIZE: 9pt" lang=EN-US>MW) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK15 (8,000) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK25 (30,000) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK30 (50,000) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK60 (400,000) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK90 (1,000,000) 

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">無熱源<***N style="FONT-SIZE: 9pt" lang=EN-US>C<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">級<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK120 (3,000,000) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、口服固體制劑的粘合劑<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在水中和一些常使用的有機溶劑中可溶，使它在許多情況下都能使用。首先，在對濕、熱敏感的藥劑，

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">用<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的乙醇溶液做粘合劑可以消除水熱等因素的影響，而對疏水性藥物，采用其水溶液可以均勻潤濕，而且

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可以藥物顆粒表面具有親水性有利于增加藥物的溶出度。此外，<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">做粘合劑可以干粉加入，在以適當(dāng)溶劑潤

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">濕制?；蜃龈烧澈蟿┲苯訅浩梢愿纳剖杷运幬锏拿撈F(xiàn)象。常用<***N style="FONT-SIZE: 9pt" lang=EN-US>K30<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">和<***N style="FONT-SIZE: 9pt" lang=EN-US>K25<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">，<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK30<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的用量一般在<***N style="FONT-SIZE: 9pt" lang=EN-US>2%--5%<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在泡騰劑中的使用，<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">是比較理想的粘合劑，因為泡騰劑要求嚴(yán)格控制水分含量，用<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的乙醇溶液做粘合劑

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就能很好地解決這個問題。由此做成的泡騰片顆?？蓞捫院茫芙庋杆?，并可強烈發(fā)泡。用約<***N style="FONT-SIZE: 9pt" lang=EN-US>5%--10%<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">液做粘合劑還可用于流化床噴霧干燥制粒。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">將雙氯芬酸鈉與淀粉、乳糖等混合，用<***N style="FONT-SIZE: 9pt" lang=EN-US>DQD <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">乙醇溶液攪拌制粒得速釋顆粒。取部分速釋顆粒繼用乙基纖維素的

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">乙醇，**溶液包衣得緩釋顆粒，上述兩種顆粒按<***N style="FONT-SIZE: 9pt" lang=EN-US>7 K 5 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">混合后裝膠囊即得。另報道胃漂浮型緩釋膠囊，顯示良

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">好的釋藥性能。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>2<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用在口服液體制劑中增稠、增粘<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在口服液體制劑中作為增稠劑的歷史已經(jīng)比較長了而且有了廣泛的應(yīng)用，比如其在乳劑和混懸劑<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK-90

<***N style="FONT-SIZE: 9pt" lang=EN-US><***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就可作為很好的增稠穩(wěn)定劑，而且聚合物是被吸附在單個膠體離子表面上形成了一薄層分子層以防止其聚結(jié)。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">進行*****透皮給藥系統(tǒng)研究中，在藥庫制備過程中就加入了<***N style="FONT-SIZE: 9pt" lang=EN-US>50%<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的<***N style="FONT-SIZE: 9pt" lang=EN-US>pvp<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">，結(jié)果證明<***N style="FONT-SIZE: 9pt" lang=EN-US>pvp<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">與<***N style="FONT-SIZE: 9pt" lang=EN-US>PVA<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">及甘油的比

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">例是影響藥庫性能的主要因素，而且如不加<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">藥庫容易干燥變硬。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">左旋氧氟沙星是目前公認的療效顯著的眼科<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">高聲傳<***N style="FONT-SIZE: 9pt" lang=EN-US>[3]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">為此研制左旋氧氟沙星滴眼劑抗菌藥。以聚*****酮

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>(PVP) <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">為增粘劑<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">制備的左旋氧氟沙星緩釋滴眼緩釋劑<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">滴入眼內(nèi)后可在眼球表面形成一層較薄的膜<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">不會像普通滴

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">眼劑那樣藥液會大部分流失<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">從而使藥物在眼部維持相對較長的治療時間<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">療效加強；而且<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶液具有一定的粘

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">度<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">流動性小<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">且透明性好<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">不影響視線<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">比現(xiàn)有的油性眼膏更具優(yōu)越性。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有文獻<***N style="FONT-SIZE: 9pt" lang=EN-US>[4]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">報道<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">加入纖維素多聚物可延長藥物與鼻粘膜接觸時間<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">從而提高藥物的療效。楊建紅<***N style="FONT-SIZE: 9pt" lang=EN-US>[5]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">等在對維生素

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>B12<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">滴鼻劑的鼻粘膜纖毛毒性評價研究中，加了<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">做增稠劑<***N style="FONT-SIZE: 9pt" lang=EN-US> 1% PV P <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶液對**上腭纖毛運動基本無影響，

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">纖毛運動相對抑制百分率均在<***N style="FONT-SIZE: 9pt" lang=EN-US>90% <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">以上。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>3<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用作固體分散體載體載體<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">提高難溶性藥物的體內(nèi)吸收一直是一個熱門的課題，要達到此目的，考慮提高其溶解度和溶解速度，固體分散體

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就是將難溶性藥物以分子、膠態(tài)、微晶或無定型態(tài)分散在一種水溶性材料中而成，能顯著提高溶出速率而更以吸

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">收。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">就是植被固體分散體常用的載體。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">楊建彬<***N style="FONT-SIZE: 9pt" lang=EN-US>[6]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">制備****固體分散體通過比較研究<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">確定****各種比例固體分散體的溶出速率與藥物原粉間均

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有顯著性差異<***N style="FONT-SIZE: 9pt" lang=EN-US>( P < 0. 05) <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">或極顯著性差異<***N style="FONT-SIZE: 9pt" lang=EN-US>( P < 0. 001) , <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出速率明顯大于藥物原粉<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">且<***N style="FONT-SIZE: 9pt" lang=EN-US>Car - PEG- 6000 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">和

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>Car - PVP <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">兩種固體分散物都顯示了同一結(jié)果<***N style="FONT-SIZE: 9pt" lang=EN-US>:<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">隨著載體量的增大<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出加快<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">但隨著載體量的增加<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出速度的增

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">加趨緩。<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作為****的載體溶出效果好于<***N style="FONT-SIZE: 9pt" lang=EN-US>PEG- 6000 , <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">且在另一老化試驗中<***N style="FONT-SIZE: 9pt" lang=EN-US>, Car - PEG- 6000 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">較<***N style="FONT-SIZE: 9pt" lang=EN-US>Car - 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">易老化<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">因此筆者認為<***N style="FONT-SIZE: 9pt" lang=EN-US>,PVP <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作為****的固體分散體載體更優(yōu)。<***N style="FONT-SIZE: 9pt" lang=EN-US>PEG - 6000 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">都是常用的固體分散

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">體載體<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">基本上都不會干擾主藥的測定。<***N style="FONT-SIZE: 9pt"> <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">****經(jīng)固體分散技術(shù)處理后<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">能顯著提高體外溶出速率<***N style="FONT-SIZE: 9pt" lang=EN-US>, <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">進而提高體

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">內(nèi)生物利用度，為****制成**制劑提供了一有效途徑。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">馬來酸羅格列酮在腸液中溶解度較小<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">推測其在腸道的吸收速率將會因此而受到影響<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">所以有必要將馬來酸羅格列

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">酮制成固體分散體<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">以增加其溶解度和溶出速率。紅外光譜分析證明二者并未發(fā)生化學(xué)反應(yīng)，<***N style="FONT-SIZE: 9pt" lang=EN-US>X-<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">射線粉末衍射分

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">析說明其是以無定型狀態(tài)分散于載體<***N style="FONT-SIZE: 9pt" lang=EN-US>PVPK30 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">中的。以水溶性材料為載體<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可通過提高藥物的可潤濕性、保證藥

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">物的高度分散性和載體材料對藥物的抑晶性而大大改善藥物的溶出與吸收。作者分別制備了<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-bidi-font-family: 宋體">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>5<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-bidi-font-family: 宋體">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>10<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-bidi-font-family: 宋體">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>15<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-bidi-font-family: 宋體">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>20(<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">藥物<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-bidi-font-family: 宋體">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP K30) <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的固體分散體<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶出速率沒有顯著性差異<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">考慮到輔料用量<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">選擇<***N style="FONT-SIZE: 9pt" lang=EN-US>1<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-bidi-font-family: 宋體">∶<***N style="FONT-SIZE: 9pt" lang=EN-US>5 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的固體分散體<***N style="FONT-SIZE: 9pt" lang=EN-US>[7]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>4<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用作薄膜包衣材料<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">通常用規(guī)格的<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">因其柔韌性較理想，可作為藥用成膜材料或與其它膜材合用。實踐已經(jīng)證明<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">能用于水和

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有機溶劑兩種系統(tǒng)的薄膜包衣工藝，其包衣的優(yōu)點：能改善膜對表面的粘附能力，改善色淀或染料的分散性，

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可作為薄膜增塑劑，可改變以疏水材料為基料的薄膜的崩解時間。包衣時的常用濃度為<***N style="FONT-SIZE: 9pt" lang=EN-US>0.5%---5%<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。目前已有

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>PVP/VA<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">系列產(chǎn)品專門用作成膜材料，它們是<***N style="FONT-SIZE: 9pt" lang=EN-US>VP(<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">**吡喏烷酮<***N style="FONT-SIZE: 9pt" lang=EN-US>)<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">與<***N style="FONT-SIZE: 9pt" lang=EN-US>VA(<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">乙酸**酯<***N style="FONT-SIZE: 9pt" lang=EN-US>)<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的共聚物。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>5<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、用在緩控釋制劑中<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在緩控釋制劑中<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可以做粘合劑，阻滯劑，促滲劑等。葉琳琳<***N style="FONT-SIZE: 9pt" lang=EN-US>[8]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">等研制了單室單層硝苯地平口服滲透泵片<***N style="FONT-SIZE: 9pt" lang=EN-US>, 

<***N style="FONT-SIZE: 9pt" lang=EN-US><***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">對硝苯地平口服滲透泵片的配方和制備參數(shù)進行優(yōu)化<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">所確定的**片芯配方，其中<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作為助滲劑含量為

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>7.08%<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">。結(jié)果表明<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">作者制備的硝苯地平滲透泵片的體外釋放較好地符合滲透泵零級釋藥特征。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>6<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP-I(<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">聚維酮碘制劑<***N style="FONT-SIZE: 9pt" lang=EN-US>) 

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP-I(<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">聚維酮碘制劑<***N style="FONT-SIZE: 9pt" lang=EN-US>)[9]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">是碘與<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">形成的一種可溶性復(fù)合物，是一種**、光譜新型殺菌劑，與碘相比具有揮

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">發(fā)性小、水溶性好、幾乎無刺激性、過敏性等優(yōu)點。目前已有許多產(chǎn)品在研或已經(jīng)上市，包括了多種劑型溶液

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">劑（皮膚用消毒劑和眼科用消毒劑）、栓劑（陰道栓、尿道栓及泡騰栓<***N style="FONT-SIZE: 9pt" lang=EN-US>[10]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">）、軟膏劑及涂劑。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>7<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、交聯(lián)<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP(CPVP )<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的應(yīng)用<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">分散片是近年來才開發(fā)的新劑型<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">日益受到重視。國外已上市的分散片品種有<***N style="FONT-SIZE: 9pt" lang=EN-US>10 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">多個<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">國內(nèi)至今已批準(zhǔn)分散片<***N style="FONT-SIZE: 9pt" lang=EN-US>28

<***N style="FONT-SIZE: 9pt" lang=EN-US> <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">種<***N style="FONT-SIZE: 9pt" lang=EN-US>(<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">同期只批泡騰片<***N style="FONT-SIZE: 9pt" lang=EN-US>11 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">種<***N style="FONT-SIZE: 9pt" lang=EN-US>) <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">但其中只有中藥品種<***N style="FONT-SIZE: 9pt" lang=EN-US>1 <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">個。分散片的崩解劑一般需要加入**崩解劑，常用的有

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><***N style="FONT-SIZE: 9pt" lang=EN-US>CPVP,L-HPC,CMS-Na<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">等。李瑞明<***N style="FONT-SIZE: 9pt" lang=EN-US>[11]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">在進行感冒靈分散片的研制中就以<***N style="FONT-SIZE: 9pt" lang=EN-US>CPVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">為崩解劑可知<***N style="FONT-SIZE: 9pt" lang=EN-US>MCC<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">與交聯(lián)<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP 

<***N style="FONT-SIZE: 9pt" lang=EN-US><***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">聯(lián)用的崩解效果較佳<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可能是因為道他們有協(xié)同作用。<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>8<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">、其它應(yīng)用<***N style="FONT-SIZE: 9pt"> <***N lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">還可用在新型的藥物釋放系統(tǒng)中，比如張學(xué)農(nóng)<***N style="FONT-SIZE: 9pt" lang=EN-US>[12]<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">阿苯達唑聚氰基******納米粒的制備、性質(zhì)及其組

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">織靶向性研究時，在納米粒制備的溶液中加入<***N style="FONT-SIZE: 9pt" lang=EN-US>4 %PVP <***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">可增大溶液粘度<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">提高載體的吸附性<***N style="FONT-SIZE: 9pt" lang=EN-US> ,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">其體外釋藥呈雙指數(shù)

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">函數(shù)<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">有<***N style="FONT-SIZE: 9pt" lang=EN-US>"<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">爆破<***N style="FONT-SIZE: 9pt" lang=EN-US>"<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">釋藥特點<***N style="FONT-SIZE: 9pt" lang=EN-US>,<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">同時可提高納米粒的物理穩(wěn)定性。此外，在注射劑的開發(fā)中，注射用<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP 12PF<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的用作增

<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">溶劑（在一些品種中藥物的溶解度明顯被<***N style="FONT-SIZE: 9pt" lang=EN-US>PVP<***N style="FONT-FAMILY: 宋體; FONT-SIZE: 9pt; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">提高）或抑晶劑應(yīng)用也越來越多。<***N style="FONT-SIZE: 9pt" lang=EN-US>

<***N style="FONT-SIZE: 9pt" lang=EN-US>?